CR11568A - Compuestos de 3h-[1,2,3]triazolo[4,5-d]pirimidina, su uso como inhibidores de mtor quinasa y pi3 quinasa y su sintesis - Google Patents

Compuestos de 3h-[1,2,3]triazolo[4,5-d]pirimidina, su uso como inhibidores de mtor quinasa y pi3 quinasa y su sintesis

Info

Publication number
CR11568A
CR11568A CR11568A CR11568A CR11568A CR 11568 A CR11568 A CR 11568A CR 11568 A CR11568 A CR 11568A CR 11568 A CR11568 A CR 11568A CR 11568 A CR11568 A CR 11568A
Authority
CR
Costa Rica
Prior art keywords
quinasa
triazolo
compounds
mtor
inhibitors
Prior art date
Application number
CR11568A
Other languages
English (en)
Inventor
Martin Dehnhardt Christoph
Mudumbai Venkatesan Aranapakam
Guillermo De Los Santos Efren
Chen Zecheng
Dos Santos Osvaldo
Brooijmans Natasja
Zask Arie
Cunera Verheijen Jeroen
Ayral-Kaloustian Semiramis
Original Assignee
Wyeth Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Llc filed Critical Wyeth Llc
Publication of CR11568A publication Critical patent/CR11568A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La invencion se refiere a compuestos de 3H-[1,2,3]triazolo[4,5-d]pirimidina de Formula 1, o una sal farmaceuticamente aceptable de los mismos, en la que las variables constituyentes son como se definen en el presente documento, a composiciones que comprenden los compuestos y a procedimientos para fabricar y usar los compuestos.
CR11568A 2008-01-15 2010-07-14 Compuestos de 3h-[1,2,3]triazolo[4,5-d]pirimidina, su uso como inhibidores de mtor quinasa y pi3 quinasa y su sintesis CR11568A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2108408P 2008-01-15 2008-01-15
US3468008P 2008-03-07 2008-03-07

Publications (1)

Publication Number Publication Date
CR11568A true CR11568A (es) 2010-08-11

Family

ID=40377318

Family Applications (1)

Application Number Title Priority Date Filing Date
CR11568A CR11568A (es) 2008-01-15 2010-07-14 Compuestos de 3h-[1,2,3]triazolo[4,5-d]pirimidina, su uso como inhibidores de mtor quinasa y pi3 quinasa y su sintesis

Country Status (21)

Country Link
US (1) US20090181963A1 (es)
EP (1) EP2252296A1 (es)
JP (1) JP2011510010A (es)
KR (1) KR20100113567A (es)
CN (1) CN102014914A (es)
AP (1) AP2010005346A0 (es)
AU (1) AU2009205501A1 (es)
BR (1) BRPI0906519A2 (es)
CA (1) CA2712267A1 (es)
CO (1) CO6321259A2 (es)
CR (1) CR11568A (es)
DO (1) DOP2010000217A (es)
EA (1) EA201001017A1 (es)
EC (1) ECSP10010346A (es)
IL (1) IL206820A0 (es)
MA (1) MA32341B1 (es)
MX (1) MX2010007746A (es)
NI (1) NI201000119A (es)
SV (1) SV2010003621A (es)
WO (1) WO2009091788A1 (es)
ZA (2) ZA201004603B (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008343813B2 (en) 2007-12-19 2012-04-12 Amgen Inc. Inhibitors of PI3 kinase
JP2011515462A (ja) * 2008-03-27 2011-05-19 アウククランド ウニセルビセス リミテッド 置換されたピリミジン、及びトリアジン、並びに癌療法におけるこれらの使用
TWI378933B (en) 2008-10-14 2012-12-11 Daiichi Sankyo Co Ltd Morpholinopurine derivatives
TW201038567A (en) * 2009-03-27 2010-11-01 Pathway Therapeutics Ltd Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
US20100331305A1 (en) * 2009-06-24 2010-12-30 Genentech, Inc. Oxo-heterocycle fused pyrimidine compounds, compositions and methods of use
CA2767008C (en) * 2009-07-07 2018-01-30 Pathway Therapeutics, Inc. Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
CA2788678C (en) 2010-02-03 2019-02-26 Signal Pharmaceuticals, Llc Identification of lkb1 mutation as a predictive biomarker for sensitivity to tor kinase inhibitors
MY170236A (en) 2010-10-06 2019-07-11 Glaxosmithkline Llc Benzimidazole derivatives as pi3 kinase inhibitors
TWI572599B (zh) 2011-03-28 2017-03-01 Ｍｅｉ製藥公司 （α－經取代之芳烷胺基及雜芳烷胺基）嘧啶基及１，３，５－三基苯并咪唑，其醫藥組合物及其在治療增生性疾病之用途
CN107375289A (zh) * 2011-11-01 2017-11-24 埃克塞利希斯股份有限公司 用于治疗淋巴组织增生性恶性肿瘤的作为磷脂酰肌醇3‑激酶抑制剂的化合物
US9499561B2 (en) 2012-04-10 2016-11-22 Shanghai Yingli Pharmaceutical Co., Ltd. Fused pyrimidine compound, and preparation method, intermediate, composition, and uses thereof
KR20160027219A (ko) 2012-05-23 2016-03-09 에프. 호프만-라 로슈 아게 내배엽 및 간세포를 수득하고 사용하는 조성물 및 방법
AU2013203714B2 (en) 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
WO2014172436A1 (en) 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer
CA2909579A1 (en) 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Combination therapy comprising a tor kinase inhibitor and n-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide for treating cancer
US9505764B2 (en) 2013-04-17 2016-11-29 Signal Pharmaceuticals, Llc Treatment of cancer with dihydropyrazino-pyrazines
CA2908742C (en) 2013-04-17 2021-06-01 Signal Pharmaceuticals, Llc Combination therapy comprising a tor kinase inhibitor and a cytidine analog for treating cancer
CN105377299B (zh) 2013-04-17 2018-06-12 西格诺药品有限公司 用于治疗前列腺癌的包含二氢吡嗪并-吡嗪化合物和雄激素受体拮抗剂的组合疗法
US9630966B2 (en) 2013-04-17 2017-04-25 Signal Pharmaceuticals, Llc Treatment of cancer with dihydropyrazino-pyrazines
CA2909629C (en) 2013-04-17 2022-12-13 Signal Pharmaceuticals, Llc Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one
NZ629486A (en) 2013-05-29 2017-11-24 Signal Pharm Llc Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-b]pyrazin-2(1h)-one, a solid form thereof and methods of their use
EP3053926B1 (en) 2013-09-30 2018-08-08 Shanghai Yingli Pharmaceutical Co. Ltd. Fused pyrimidine compound, intermediate, preparation method therefor, and composition and application thereof
US9512129B2 (en) 2014-04-16 2016-12-06 Signal Pharmaceuticals, Llc Solid forms comprising 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one and a coformer
NZ714742A (en) 2014-04-16 2017-04-28 Signal Pharm Llc Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
KR20170002623A (ko) 2014-05-14 2017-01-06 화이자 인코포레이티드 피라졸로피리딘 및 피라졸로피리미딘
WO2017087818A1 (en) * 2015-11-19 2017-05-26 The Regents Of The University Of Michigan Dual src/p38 kinase inhibitor compounds and their use as therapeutic agents
US11304953B2 (en) 2017-05-23 2022-04-19 Mei Pharma, Inc. Combination therapy
TWI787284B (zh) 2017-06-22 2022-12-21 美商西建公司 以b型肝炎病毒感染表徵之肝細胞癌之治療
US12054488B2 (en) * 2018-09-27 2024-08-06 Suzhou Raymon Pharmaceuticals Company, Ltd. Pyrazolopyrimidine compound and preparation method therefor and use thereof in preparation of anti-cancer drug
CN113549080B (zh) * 2021-08-27 2023-05-16 中国医学科学院放射医学研究所 一类1,2,3-三氮唑并嘧啶类化合物、其制备方法和用途
KR20240015978A (ko) 2022-07-28 2024-02-06 박수산 다층 수력 발전시스템
GB202415232D0 (en) 2024-10-16 2024-11-27 Nacamed As Composition

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100774855B1 (ko) * 2000-04-27 2007-11-08 아스텔라스세이야쿠 가부시키가이샤 축합 헤테로아릴 유도체

Also Published As

Publication number Publication date
DOP2010000217A (es) 2010-07-31
KR20100113567A (ko) 2010-10-21
NI201000119A (es) 2011-05-04
CN102014914A (zh) 2011-04-13
EA201001017A1 (ru) 2011-02-28
ZA201004603B (en) 2011-03-30
EP2252296A1 (en) 2010-11-24
ECSP10010346A (es) 2010-08-31
AU2009205501A1 (en) 2009-07-23
ZA201005793B (en) 2011-04-28
BRPI0906519A2 (pt) 2015-07-14
SV2010003621A (es) 2011-07-05
MA32341B1 (fr) 2011-06-01
WO2009091788A1 (en) 2009-07-23
US20090181963A1 (en) 2009-07-16
IL206820A0 (en) 2010-12-30
AP2010005346A0 (en) 2010-08-31
JP2011510010A (ja) 2011-03-31
CO6321259A2 (es) 2011-09-20
CA2712267A1 (en) 2009-07-23
MX2010007746A (es) 2010-08-18

Similar Documents

Publication Publication Date Title
CR11568A (es) Compuestos de 3h-[1,2,3]triazolo[4,5-d]pirimidina, su uso como inhibidores de mtor quinasa y pi3 quinasa y su sintesis
NI201000060A (es) COMPUESTOS DE TIENOPIRIMIDINA Y PIRAZOLOPIRIMIDINA Y SU USO COMO INHIBIDORES DE mTOR CINASA Y PI3 CINASA.
UY30334A1 (es) Derivados de triazolopirazina
ECSP10010556A (es) Piridinas y pirazinas como inhibidores de pi3k
UY30327A1 (es) Nuevos compuestos ii
DOP2012000150A (es) Triazolopiridinas
UY30500A1 (es) Compuestos de azabencimidazolilo
CL2010001348A1 (es) Compuestos derivados de 1-oxo-2,3-dihidro-1h-isoindolin-5-il)-isoxazol-3-carboxamida, potenciadores de los mglur2; composicion farmaceutica; y su uso para aliviar los sintomas o disminuir la aparicion de los sintomas de ezquizofrenia o ansiedad.
UY29781A1 (es) Compuestos diazaspiro sustituidos, sales farmacéuticamente aceptables, composiciones farmacéuticas que contienen los compuestos o sales, métodos de preparación y usos
CU23777B7 (es) Piridin[3,4-b]pirazinonas
ECSP109856A (es) Derivados de oxadiazol y su uso como potenciadores de los receptores metabotrópicos de glutamato - 842
CU20140068A7 (es) Triazolopiridinas sustituidas
ECSP12012338A (es) Triazolopiridinas sustituidas
ECSP13013011A (es) Triazolopiridinas
UY29469A1 (es) Compuestos sulfoximino-macrocíclicos y sus sales, composiciones farmacéuticas que comprenden dichos compuestos, métodos de preparación y usos de los mismos.
CR10304A (es) Compuestos de tetrahidropiridotienopirimidina y procedimientos de uso de los mismos
CR11208A (es) Derivados de pirimidina utiles para el tratamiento de condiciones inflamatorias o alergicas
GT200500360A (es) Compuestos organicos
CR10199A (es) Derivados de benzimidazol
ECSP099506A (es) Derivados de 2-quinolinona y 2 quinoxalinona y su utilización como agentes anti bacterianos
CU20110108A7 (es) [4-(1-amino-etil)-ciclohexil]-metil-aminas como antibacterianos
CU20100148A7 (es) Compuestos de 3h-[1,2,3]triazolo[4,5-d]pirimidina, su uso como inhibidores de mtor quinasa y pi3 quinasa y su síntesis
UY30849A1 (es) S-nitrosotioles estables, procedimeinto de sintesis y uso
CU23681B7 (es) Derivados de triazolopirazina
DOP2007000096A (es) Derivados de triazolopirazina

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)